Frequently, these bispecific antibodies target one tumour antigen (e.g., CD19 or CD20 in B-cell lymphomas) and one immune-related molecule (e.g., CD3), aiming at redirecting T cells against tumour cells and working as cytotoxic T-cell engagers [196]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.